Eli Lil­ly joins a troi­ka of Big Phar­mas that have tied up to a low-pro­file biotech with big as­pi­ra­tions in au­toim­mune dis­ease, can­cer

Eli Lil­ly has fol­lowed 3 ma­jor league phar­ma play­ers down the deal path to Im­muNext, a biotech you may not know a whole lot about.

The low-pro­file biotech has re­served one seg­ment of the R&D mis­sion for im­munome­tab­o­lism, study­ing how you could reg­u­late the im­mune sys­tem so that it would stop at­tack­ing healthy tis­sue, of­fer­ing a new ap­proach to au­toim­mune dis­eases. Their pre­clin­i­cal pro­gram fo­cus­es on reg­u­lat­ing im­mune cell me­tab­o­lism. And that’s where Lil­ly is step­ping on board, join­ing the pro­gram with an aim to ad­vance in­to hu­man stud­ies.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER